{"id":"polatuzumab-vedotin-rituximab-lenalidomide","safety":{"commonSideEffects":[{"rate":"44%","effect":"Neutropenia"},{"rate":"34%","effect":"Anemia"},{"rate":"29%","effect":"Thrombocytopenia"},{"rate":"24%","effect":"Fatigue"},{"rate":"22%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Polatuzumab vedotin is a monoclonal antibody-drug conjugate that targets CD19 on B cells and delivers a microtubule inhibitor to induce cell death.","oneSentence":"Monoclonal antibody targeting CD19, conjugated with microtubule inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:05:20.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diffuse large B-cell lymphoma"},{"name":"Follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":"Non-Hodgkin Lymphoma","enrollment":496},{"nctId":"NCT06803693","phase":"PHASE2","title":"Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":152},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT06664411","phase":"PHASE2","title":"Pola-ZR2P in Previously Untreated DLBCL","status":"RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2024-09-24","conditions":"Diffuse Large B-cell Lymphoma","enrollment":80},{"nctId":"NCT07122609","phase":"PHASE2","title":"Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-05","conditions":"Relapsed and Refractory DLBCL","enrollment":22},{"nctId":"NCT06522555","phase":"PHASE3","title":"The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-07-29","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":100},{"nctId":"NCT06516978","phase":"PHASE2","title":"A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":528},{"nctId":"NCT06441097","phase":"PHASE2","title":"Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-31","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":152},{"nctId":"NCT02600897","phase":"PHASE1, PHASE2","title":"A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-24","conditions":"Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":114},{"nctId":"NCT06176729","phase":"PHASE2","title":"Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients","status":"RECRUITING","sponsor":"Yan Zhang, MD","startDate":"2023-10-24","conditions":"Diffuse Large B Cell Lymphoma","enrollment":30},{"nctId":"NCT04882163","phase":"PHASE1, PHASE2","title":"Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma","status":"WITHDRAWN","sponsor":"Celgene","startDate":"2021-10-10","conditions":"Lymphoma, B-Cell","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Polatuzumab Vedotin, Rituximab, Lenalidomide","genericName":"Polatuzumab Vedotin, Rituximab, Lenalidomide","companyName":"Yan Zhang, MD","companyId":"yan-zhang-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Monoclonal antibody targeting CD19, conjugated with microtubule inhibitor Used for Diffuse large B-cell lymphoma, Follicular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}